このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

p-PHOTOLARYNX- ANTHEM: Photon-Counting CT in Laryngeal Cancer Staging (H&NRAD-2025-01)

2026年5月19日 更新者:Caterina Giannitto、Humanitas University

p-PHOTOLARYNX- ANTHEM: Pilot Photon-Counting CT Evaluation of the Paraglottic Space and Cartilage Involvement in Laryngeal Cancer

Laryngeal cancer can affect speaking, swallowing, and breathing. Treatment selection depends on accurately defining tumor spread within the larynx, particularly invasion of the paraglottic space, thyroid cartilage, and subglottic region. Understaging may lead to insufficient treatment and recurrence, whereas overstaging may result in unnecessarily aggressive surgery and impaired quality of life.

CT and MRI are routinely used for local staging, but both have limitations. Conventional CT may have limited soft-tissue and cartilage contrast, while MRI is more time-consuming, motion-sensitive, and not feasible in all patients. Photon-counting CT (PCCT) is a new CT technology offering higher spatial resolution, improved tissue contrast, and reconstructions at different energy levels.

This study evaluates whether PCCT performed during phonation, while the patient produces a sustained sound, can improve local staging of laryngeal cancer. Phonation may better separate and display laryngeal structures, improving detection of tumor extension.

The main hypothesis is that optimized phonation PCCT reconstructions can assess tumor spread more accurately than standard CT and may approach MRI performance. Participants undergo PCCT as part of routine preoperative imaging. Images are reconstructed using different settings and reviewed by radiologists for image quality and tumor extension. When surgery is performed, imaging findings are compared with surgical and histopathological results.

The study aims to identify the most accurate PCCT reconstruction strategy to support better treatment planning in laryngeal cancer.

調査の概要

状態

招待による登録

詳細な説明

This is a prospective, single-center observational imaging study designed to evaluate the diagnostic performance of photon-counting computed tomography (PCCT) acquired during phonation for local staging of biopsy-proven laryngeal squamous cell carcinoma.

Study Overview and Imaging Workflow

Eligible adult patients with histologically confirmed laryngeal squamous cell carcinoma referred for preoperative imaging undergo contrast-enhanced PCCT as part of routine clinical work-up. PCCT examinations are performed on a dedicated photon-counting CT system using a standardized acquisition protocol optimized for ultra-high-resolution imaging of the larynx during phonation. Imaging is acquired in the venous phase under sustained vocalization to enhance functional and morphological assessment of glottic and subglottic structures.

For each acquisition, multiple reconstructions are generated, including ultra-high-resolution virtual monoenergetic images (VMIs) at predefined energy levels and different reconstruction kernels. A 70-keV reconstruction with standard slice thickness is included as an energy-integrating detector (EID)-CT-like reference. When available, previously acquired conventional CT and/or MRI performed as part of standard care are included for comparative analysis. Surgical histopathology serves as the reference standard for local tumor extension.

Qualitative Image Assessment

Qualitative analysis is restricted to phonation acquisitions to maximize clinical relevance and reduce reader burden. Four expert head and neck radiologists independently review anonymized and randomized datasets, blinded to reconstruction parameters. For each dataset, readers assign a qualitative diagnostic quality score using a five-point Likert scale and evaluate tumor extension into the paraglottic space, thyroid cartilage (with distinction between inner cortical erosion and full-thickness invasion), and subglottic space using predefined ordinal scoring systems. Multiplanar reformations aligned with the glottic plane and axis are mandatorily assessed as part of each dataset.

Quantitative Image Assessment

Quantitative analysis is performed by two independent observers on a dedicated workstation. Standardized regions of interest (ROIs) are placed in the primary tumor, adjacent non-tumoral laryngeal tissues, subcutaneous fat (for noise estimation), and the common carotid artery (vascular reference). ROIs are defined on a representative axial slice and propagated across all reconstructions to ensure measurement consistency. Quantitative metrics include attenuation values, image noise, signal-to-noise ratio (SNR), and contrast-to-noise ratio (CNR).

Data Management and Quality Assurance

Data are collected using structured electronic case report forms (eCRFs) derived from hospital source documents. All imaging data are anonymized prior to analysis. Quality assurance procedures are based on written standard operating procedures at the sponsor site and include verification of data completeness, internal consistency checks, and cross-validation of imaging assessments with source data (radiology reports, surgical and pathology records). Access to source data is permitted for authorized personnel in accordance with Good Clinical Practice and data protection regulations.

Statistical Analysis Plan

Given the exploratory, pilot nature of the study, the planned sample size of 60 patients is based on feasibility and the need to support descriptive and comparative multi-dataset, multi-reader analyses rather than formal hypothesis testing. Quantitative variables are summarized using appropriate descriptive statistics based on data distribution. Interobserver agreement is assessed using intraclass correlation coefficients for quantitative measures and Fleiss' kappa for ordinal qualitative scores.

The effects of VMI energy level and reconstruction kernel on quantitative and qualitative outcomes are evaluated using mixed-effects models accounting for repeated measures within patients and readers. Diagnostic performance of PCCT, and where available conventional CT and MRI, is assessed using sensitivity, specificity, predictive values, and receiver operating characteristic analysis with histopathology as the reference standard. Adjustment for multiple comparisons is applied when appropriate.

Handling of Missing Data

Missing or non-evaluable data (e.g., due to severe artifacts or unavailable histopathology) are documented explicitly. Analyses are primarily conducted on available data without imputation, and sensitivity analyses may be performed to assess the impact of missing values.

Ethical and Operational Considerations

The study does not modify standard clinical management. No study-specific adverse events are anticipated. All procedures comply with the Declaration of Helsinki, Good Clinical Practice, and applicable regulatory requirements. Written informed consent is obtained prior to participation.

研究の種類

観察的

入学 (推定)

60

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Rozzano、イタリア、20089
        • Humanitas Research Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

サンプリング方法

確率サンプル

調査対象母集団

A total of sixty patients, with biopsy-proven laryngeal squamous cell carcinoma will be enrolled in the study.

説明

1. SELECTION CRITERIA

Inclusion Criteria

  • Adults (≥18 years)
  • Biopsy-proven laryngeal cancer squamous cell carcinoma
  • Candidate for surgical staging able to undergo PCCT

Exclusion criteria

  • Renal failure
  • Allergy to contrast medium
  • Refusal of informed consent
  • Lack of histopathologic confirmation
  • Histopathologic diagnosis of non laryngeal tumors
  • Poor image quality due to severe artifacts

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
介入・治療
Biopsy-Proven Laryngeal Squamous Cell Carcinoma Patients
A total of sixty patients, with biopsy-proven and clinical laryngeal squamous cell carcinoma
Photon-Counting CT (PCCT) will be performed using the Siemens Healthineers NAEOTOM Alpha, the latest generation of CT technology and the first system to apply photon-counting detector technology to laryngeal imaging. Its CdTe detectors count individual photons and measure their energy, enabling true spectral imaging with ultra-high spatial resolution (voxel size down to 0.2 mm). Multi-energy maps significantly improve tissue differentiation, allowing clearer distinction between paraglottic fat, non-ossified thyroid cartilage, and tumor tissue. The technology also reduces artifacts and enhances contrast, enabling detailed evaluation of the laryngeal cartilages and paraglottic space.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Diagnostic Accuracy of Phonation Photon-Counting CT (PCCT) for Local Tumor Extension
時間枠:From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.

Description:

To evaluate the diagnostic accuracy of phonation PCCT in identifying paraglottic space invasion, thyroid cartilage invasion (including distinction between inner cortical erosion and full-thickness invasion), and subglottic extension, using surgical and histopathological findings as the reference standard.

From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.
Identification of the Optimal PCCT Reconstruction for Local Staging
時間枠:From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.
To identify the best-performing phonation PCCT reconstruction (defined by VMI energy level and reconstruction kernel) for each anatomical target (paraglottic space, thyroid cartilage, subglottic space), based on diagnostic accuracy relative to histopathology.
From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.

二次結果の測定

結果測定
メジャーの説明
時間枠
Robustness of Local Staging Across PCCT Reconstructions
時間枠:From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.
To assess variability in local staging classification (paraglottic space invasion, cartilage involvement, subglottic extension) across different phonation PCCT reconstructions, including staging upgrades or downgrades between datasets.
From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.
Interobserver Agreement for Qualitative and Staging Assessments
時間枠:From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.

To evaluate interobserver reproducibility among readers for qualitative diagnostic quality scores and ordinal staging assessments of paraglottic space invasion, cartilage involvement, and subglottic extension.

.

From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.
Tumor attenuation
時間枠:At baseline imaging, before surgery.
Mean attenuation measured in Hounsfield Units (HU) within tumor regions of interest.
At baseline imaging, before surgery.
Image noise
時間枠:At baseline imaging, before surgery.
Image noise defined as the standard deviation of attenuation measured in a homogeneous region (e.g., subcutaneous fat).
At baseline imaging, before surgery.
Signal-to-noise ratio (SNR)
時間枠:At baseline imaging, before surgery.
Signal-to-noise ratio calculated as mean tumor attenuation divided by image noise.
At baseline imaging, before surgery.
Contrast-to-noise ratio (CNR)
時間枠:At baseline imaging, before surgery.
Contrast-to-noise ratio calculated as the difference in attenuation between tumor and reference tissue divided by image noise.
At baseline imaging, before surgery.
CT dose index volume (CTDIvol)
時間枠:At baseline imaging, before surgery.
Volume CT dose index measured in milligray (mGy)
At baseline imaging, before surgery.
Dose-length product (DLP)
時間枠:At baseline imaging, before surgery.
Dose-length product measured in milligray-centimeters (mGy·cm).
At baseline imaging, before surgery.
Effective dose
時間枠:At baseline imaging, before surgery.
Estimated effective radiation dose expressed in millisieverts (mSv).
At baseline imaging, before surgery.
Comparison of PCCT with Conventional CT and MRI
時間枠:From completion of phonation PCCT imaging to completion of multimodality image review and histopathological correlation, assessed up to 12 weeks.
To compare the diagnostic performance of phonation PCCT with conventional energy-integrating detector CT and MRI, when available, using histopathology as the reference standard.
From completion of phonation PCCT imaging to completion of multimodality image review and histopathological correlation, assessed up to 12 weeks.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年5月16日

一次修了 (推定)

2026年5月31日

研究の完了 (推定)

2027年5月31日

試験登録日

最初に提出

2025年12月27日

QC基準を満たした最初の提出物

2026年5月19日

最初の投稿 (実際)

2026年5月22日

学習記録の更新

投稿された最後の更新 (実際)

2026年5月22日

QC基準を満たした最後の更新が送信されました

2026年5月19日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

IPD プランの説明

At the time of registration, no final decision has been made regarding sharing of individual participant data. Any future data sharing would be subject to ethical approval, data protection regulations, and appropriate data use agreements.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する